• Incannex received A$ 5.1 million from Australia’s R&D Tax Incentive Program following approval of overseas findings for FY25.
• Total 2026 proceeds under the program reached more than A$ 11.2 million in non-dilutive funding.
• Cash inflow supports clinical development programs, including IHL-42X and PSX-001.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-087493), on August 11, 2026, and is solely responsible for the information contained therein.